Trial Profile

A Phase 1 Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses of PGN-EDODM1 in Adult Participants With Myotonic Dystrophy Type 1 (FREEDOM-DM1)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Nov 2025 According to a Pepgen Inc media release, the company reported topline results from the 15 mg/kg cohort of PGN-EDODM1.
12 Nov 2025 According to a Pepgen Inc media release, In October 2025, PepGen gave an oral presentation at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting which included a review of the FREEDOM clinical data.
12 Nov 2025 According to a Pepgen Inc media release, data from this study was featured in an oral presentation in Oct 2025 at the 30th Annual International Congress of the World Muscle Society (WMS).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com